Sareum Ltd

📍 Pampisford, United Kingdom🗓 Founded 2003👥 6 employees💰 Last funded Jan 2016
Biotechnology🌐 sareum.com
Website LinkedIn
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis. Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Sareum Ltd?
Sareum Ltd has 1 investors on record on gritt.io.
When did Sareum Ltd last raise funding?
The most recent investment in Sareum Ltd recorded on gritt.io was in January 2016.
When was Sareum Ltd founded?
Sareum Ltd was founded in 2003.
What industry is Sareum Ltd in?
Sareum Ltd operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Sareum Ltd based?
Sareum Ltd is headquartered in Pampisford, United Kingdom.